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Abstract
Background:  New legal regulations for the marketing of pharmaceutical products were
introduced in 2002 in Switzerland. We investigated whether claims in drug advertisements citing
published scientific studies were justified by these studies after the introduction of these new
regulations.
Methods: In this cross-sectional study, two independent reviewers screened all issues of six major
Swiss medical journals published in the year 2005 to identify all drug advertisements for analgesic,
gastrointestinal and psychopharmacologic drugs and evaluated all drug advertisements referring to
at least one publication. The pharmaceutical claim was rated as being supported, being based on a
potentially biased study or not to be supported by the cited study according to pre-specified
criteria. We also explored factors likely to be associated with supported advertisement claims.
Results:  Of 2068 advertisements 577 (28%) promoted analgesic, psychopharmacologic or
gastrointestinal drugs. Among them were 323 (56%) advertisements citing at least one reference.
After excluding multiple publications of the same drug advertisement and advertisements with non-
informative references, there remained 29 unique advertisements with at least one reference to a
scientific study. These 29 advertisements contained 78 distinct pairs of claims of analgesic,
gastrointestinal and psychopharmacologic drugs and referenced studies. Thirty-seven (47%) claims
were supported, 16 (21%) claims were not supported by the corresponding reference, and 25
(32%) claims were based on potentially biased evidence, with no relevant differences between drug
groups. Studies with conflict of interest and studies stating industry funding were more likely to
support the corresponding claim (RR 1.52, 95% CI 1.07–2.17 and RR 1.50, 95% CI 0.98–2.28) than
studies without identified conflict of interest and studies without information on type of funding.
Conclusion: Following the introduction of new regulations for drug advertisement in Switzerland,
53% of all assessed pharmaceutical claims published in major medical journals are not supported by
the cited referenced studies or based on potentially biased study information. In light of the
discrepancy between the new legislation and the endorsement of these regulations, physicians
should not trust drug advertisement claims even when they seem to refer to scientific studies.
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Background
Drug advertisement is an effective tool to form physicians'
perception of drug efficacy and prescription behaviour [1-
4]. Advertisement claims of pharmaceutical companies
have been criticized for making exaggerated claims,
emphasizing relative over absolute effect measures [5],
omission of adverse effects, and for use of different stand-
ards for promoting drugs in resource-limited countries
[6].
In step with the growing importance of evidence-based
medicine, we have observed the pharmaceutical industry
in Switzerland increasingly including bibliographical ref-
erences in drug advertisements to give apparent support to
promotional claims. The accuracy of drug advertisements
in medical journals and direct-to consumer advertise-
ments in relation to cited scientific material has been
addressed by various investigations and inaccurate or mis-
leading claims in drug advertisements have been identi-
fied [7-16].
On January 1st 2002, Switzerland introduced the new Fed-
eral Act on Therapeutic Products that defines new regula-
tions for the marketing of pharmaceutical products [17].
The law requires that advertisements claims "have to be
accurate, balanced and supported by evidence". Market-
ing claims must "reflect current scientific knowledge" and
"only studies conducted according to good clinical prac-
tice" may be cited. Claims in advertisements "must be
quoted accurately, completely and need to be exactly ref-
erenced" [17].
In this study, we evaluate the accuracy of advertisement
claims by the pharmaceutical industry that have been
published in the six most widespread medical journals in
Switzerland 3 years following the introduction of the new
Federal Act on Therapeutic Products. In addition, we eval-
uated whether claims were based on potentially biased
studies. We also explored factors likely to be associated
with supported advertisement claims such as claims refer-
ring to studies with industry funding, claims referring to
studies with potential conflict of interest, and claims refer-
ring to studies with double blind study design.
We assumed that this time period would be sufficient to
allow for the adaptation to the new requirements. We
focused our research on claims in pharmaceutical adver-
tisements for analgesic, gastrointestinal and psychophar-
macologic drugs for three reasons. They belong to the
most frequently prescribed drugs in primary care, no pre-
vious study has addressed the adequacy of advertisement
claims for these drug categories and because we expected
referenced studies relating to these drugs report functional
or quality of life related endpoints that are of immediate
importance to patients.
Methods
In this cross-sectional study, we screened all issues of six
major Swiss medical journals [18-23], including the offi-
cial weekly organ of the Swiss Medical Association (FMH)
[20] published in the year 2005 to identify all drug adver-
tisements for analgesic, gastrointestinal and psychophar-
macologic drugs (Table 1). Five of these journals target
general practitioners and internists in Switzerland.
Table 1: Drug advertisement in 6 major Swiss medical journals in the year 2005
Journal name Swiss Medical 
Weekly[18]
Schweizerische 
Ärztezeitung[20]
Swiss Medical 
Forum[19]
Therapeutische 
Umschau[22]
Therapiewoche[2
3]
Ars Medici[21]
Issues per year 
(2005)
48 52 52 12 12 26
Peer reviewed Yes No Yes Yes No No
Listed in Medline Yes Yes Yes Yes No No
Type of subscription By charge By membership By membership By charge Free of charge Free of charge
Circulation 
(copies per issue)
1600 34800 34800 3000 5000 9500
Total Pages: 715 2845 1312 800 270 1152
Pages with drug 
advertisements
68 (8.6%) 751 (20.2%) 555 (26.8%) 249 (22.2%) 73 (19.5%) 372 (23%)
Pages by drug 
category
22 117 52 24 12
- Analgesic 
drugs
87 8 5 9 1 4 7 5 0
- 
Psychopharma
cological drugs
23 3 3 11 1 1 3 4
- 
Gastroenterol
ogical drugs
22BMC Medical Informatics and Decision Making 2008, 8:61 http://www.biomedcentral.com/1472-6947/8/61
Page 3 of 9
(page number not for citation purposes)
Two reviewers first independently quantified the total
number of advertisements, and then the number of
unique advertisements. Thereafter they independently
evaluated all drug advertisements referring to at least one
scientific publication according to pre-specified criteria.
We abstracted from each cited study data on the type of
study (systematic review or meta-analysis, randomised
controlled trial, cohort study, case control study, case
series, or narrative review), financial source of support,
declaration of potential conflict of interest, six quality cri-
teria for randomised controlled trials, the type of study
endpoint (clinical or surrogate endpoint) and whether
endpoints were specified as primary, secondary, or not
pre-specified (post hoc).
Advertisements were independently categorised into the
following categories of claims: efficacy, reduction in
adverse effects (safety), cost (reduced costs or better cost-
effectiveness ratio), and dosage/convenience (simplified
dosing or ease of use). We then classified claims as sup-
ported, not supported or based on potentially biased evi-
dence. Claims with vague or general statements that could
not be verified by a referenced study were excluded from
our analysis such as claims referring to the Swiss Drug
Compendium, the standard reference book for drugs
licensed in Switzerland [24].
A claim was rated as not being supported by the cited
study, if one of the following criteria applied: false state-
ment, absence of relation, exaggeration of efficacy, unjus-
tified generalization or unjustified transfer to humans.
False statement was defined as a statement that contra-
dicted the findings of the cited study. An absence of rela-
tion existed if the advertising claim had no relation with
the study referenced or the claim made by the advertising
could not be inferred from the cited study. A study was
rated as exaggerating efficacy if the statement from the
advertisement mentioned a higher effect size that did not
correspond with the effect size in the original study.
Unjustified generalization was defined as an advertising
claim that targeted patient groups other than patients
evaluated in the cited study (e.g. different age or gender
groups). If an effect was observed in-vitro or in animal
studies only, we rated the claim as representing an unjus-
tified transfer of results to humans.
An advertising claim was rated as being based on a poten-
tially biased study if the cited study failed at least 3 out of
the following 6 quality criteria for the design or reporting
of randomised controlled trials: the trial was an open
study, where neither the patients nor the physicians or
outcome assessor were blinded; if studies provided insuf-
ficient information about the presence or absence of con-
cealed treatment allocation; if the number of patients lost-
to-follow-up was more than 10%; if there were no reasons
for drop outs reported; if there was selective reporting of
positive outcomes in a study with positive and negative
outcomes; and if no intention-to-treat analysis was per-
formed. Furthermore, claims were rated as being based on
potentially biased studies if cited studies referred to obser-
vational studies or to abstracts of randomised controlled
trials that had not gone through a peer-review process; if
there was an obvious selection bias (i.e., claim referred to
case series, cohort study or to a randomised controlled
trial where patients not responding or experiencing side
effects to a certain drug were already excluded in the run-
in-phase of the trial); if the study was based on a post-hoc
analysis; and if the cited study was a narrative review
(publication bias) unless the claim could be clearly sub-
stantiated or proved wrong by the narrative review. A
claim was rated as supported if none of the above applied.
Disagreement between the two reviewers concerning the
nature of the pharmaceutical claim, the quality of the
studies and/or the decision of whether the claim was sup-
ported, not supported or based on potentially biased evi-
dence was resolved by consensus. Where no consensus
was possible, a third independent reviewer was asked to
state his opinion.
The primary outcome of interest was the rate of claims
supported, not supported or based on potentially biased
evidence. We a priori additionally explored factors likely
to be associated with supported advertisement claims
such as funding of a study through the industry, potential
conflict of interest of study authors, and double blind ver-
sus open randomised trials. We assumed presence of con-
flict of interest when at least one of the listed authors was
employed by the drug company producing the marketed
drug as evident from address information of each author
even though no conflict of interest was officially declared.
Statistics
We used descriptive statistics to report proportions of
advertisement claims for each of the evaluated drug
groups and to present the proportions of claims as being
supported, not supported or being based on potentially
biased evidence. We calculated risk ratios to evaluate
whether author's conflict of interest or indication of
industry funding increase the likelihood of supported
claims. Kappa statistics were calculated for the agreement
between the reviewers as to the classification of the claims
as being supported, not supported or being based on
potentially biased evidence [25]. All statistical analyses
were conducted using Stata 9.2 (StataCorp, College Sta-
tion, Texas, USA).
Results
Characteristics of the screened six medical journals are
summarised in Table 1. On average, 20% of pages in theseBMC Medical Informatics and Decision Making 2008, 8:61 http://www.biomedcentral.com/1472-6947/8/61
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journals were allocated to drug advertisements (range 9%
to 27%). There were a total of 2068 drug advertisements
and of those 577 (28%) promoted analgesic, psychophar-
macologic or gastrointestinal drugs. Among them were
323 (56%) advertisements citing at least one reference.
After excluding multiple publications of the same drug
advertisement and advertisements with non-informative
references such as references referring to the Swiss Drug
Compendium only, there remained 29 unique advertise-
ments with at least one reference to a scientific study. All
cited studies could be located. The 29 unique advertise-
ments contained 76 distinct claims [Figure 1]. Sixteen of
these claims did not refer to clinical studies. Most claims,
(n = 66, 84%) described the qualitative effectiveness of
the drug. Six claims (8%) qualitatively praised the drug's
safety profile, 3 claims (4%) mentioned dosage advan-
tages, and one claim was about a financial incentive.
Among the 60 claims referring to clinical studies some
claims quoted multiple references. In total, we were able
to evaluate 78 distinct pairs of claims and referenced stud-
ies [Table 2]. Referenced studies comprised 51 (65%) ran-
domised controlled trials (RCTs), 10 (13%) narrative
reviews, 7 (9%) cohort studies, 4 (5%) meta-analyses or
systematic reviews and 6 (7%) other types of studies (e.g.
case series or laboratory studies). Sixty-seven studies
(86%) addressed clinical endpoints and 11 studies (14%)
reported surrogate endpoints.
Forty-one studies of the 78 claim-study pairs (53%) did
not provide any information about the financial source of
the study, 35 studies (45%) were industry funded, and
one study each was sponsored by a non-profit organiza-
tion (1%) or combined funding from a profit and a non-
profit organization (1%). No study reported authors' con-
flict of interest, although we identified a conflict in 47 of
studies (60%) where at least one of the listed authors was
employed by the drug company producing the marketed
drug.
Accuracy of Pharmaceutical Claims
Thirty-seven (47%) claims were supported and 16 (21%)
claims were not supported by the corresponding refer-
ence, 25 (32%) claims were rated to be based on poten-
tially biased evidence with no relevant differences
between drug groups [Table 2]. The kappa statistics for
agreement of claims rated as supported, not supported
and being based on potentially biased evidence were 0.77,
0.73, and 0.71, respectively. Reasons for not supported
claims were false statements in 4 claims (24%), exaggera-
Table 2: Non-supported claims and claims based on potentially biased evidence of drug advertisements in major Swiss medical journals 
in 2005
Total Supported claims Not supported claims Claims based on potentially biased evidence
Drug claims 78 37 (47%) 16 (21%) 25 (32%)
Analgesic drugs 32 14 (44%) 10 (31%) 8 (25%)
Psychopharmacologic drugs 30 17 (57%) 3 (10%) 10 (33%)
Gastrointestinal drugs 16 6 (38%) 3 (19%) 7 (43%)
Promotional claims
Effectiveness 66(85%) 31 (84%) 14 (88%) 21 (84%)
Safety 6 (8%) 2 (5%) 1 (6%) 3 (12%)
Dosage/convenience 3 (4%) 1 (3%) 1 (6%) 1 (4%)
Neutral 2 (3%) 2 (5%)
Costs 1 (1%) 1 (3%)
Type of non-supported claim
False statement 4 (25%)
Exaggeration 4 (25%)
Unjustified generalization 3 (19%)
Absence of relation 3 (19%)
Unjustified transfer to humans 2 (13%)
Type of claims based on potentially biased 
evidence
Abstract only 9 (36%)
Selection bias 6 (24%)
Publication bias 5 (20%)
Information of ≥ 3 quality items of RCT* 
missing
4 (16%)
Post hoc analysis 1 (4%)
RCT*, randomised controlled trialBMC Medical Informatics and Decision Making 2008, 8:61 http://www.biomedcentral.com/1472-6947/8/61
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Number of advertisements and claims with references in the study Figure 1
Number of advertisements and claims with references in the study. * The Swiss Drug Compendium is the standard 
reference book for drugs licensed in Switzerland [29].
2068 Drug advertisements
277 Advertisements with 
analgesic drugs
200 Advertisements with 
psychopharmacological drugs
100 Advertisements with 
gastrointestinal drugs
147 Advertisements with 
references
113 Advertisements with 
references
63 Advertisements with 
references
12 Distinct advertisements with 
references
11 Distinct advertisements with 
references
6 Distinct advertisements with 
references
28 Claims with references  29 Claims with references  19 Claims with references  
76 Claims with at least one 
reference
60 Claims with at least one 
reference evaluated 
- 45 Claims quoted 1 reference  
- 13 Claims quoted 2 references 
-   1 Claim quoted 3 references 
-   1 Claim quoted 4 references
16 Claims not evaluated 
 - 12 Quoted Swiss Drug 
       Compendium* 
  -  4 Descriptive only
78 Comparisons claim-studyBMC Medical Informatics and Decision Making 2008, 8:61 http://www.biomedcentral.com/1472-6947/8/61
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tions of efficacy in 4 claims (24%), unjustified generaliza-
tions in 3 claims (19%), absence of relation in 3 claims
(19%), and unjustified transfer to humans in 2 (13%)
claims. Reasons for potentially biased claims were claims
referring to abstracts only (n = 9, 36%), to studies with
selection bias (n = 6, 24%), to studies suffering from pub-
lication bias (n = 5, 20%), to randomised trials with three
or more quality criteria not being reported (n = 4, 16%),
and to one study reporting a post-hoc analysis (n = 1,
4%). Examples of each category of not supported or
potentially biased claims are provided in Tables 3 and 4.
For example, a striking unjustified transfer to humans was
a claim for Duspatalin® (mebeverine) stating that Duspa-
talin® "is effective in all cases of irritable bowel syndrome"
with a reference to a study investigating the drug's effect in
the bowel of pigs [26]. Another advertisement promoting
Duphalac® (lactulose) as having a "fast and permanent
effect in constipation" referred to a study limited to eval-
uation of the effect of lactulose on the composition of
bowel flora [27].
Association of claims referring to industry-funded studies 
and studies with potential conflict of interest with 
supported advertisement claims
Advertisement claims were more likely to be supported by
referenced studies where at least one author had a conflict
than studies without identified conflict of interest (RR
1.52, 95% CI 1.07–2.17). Similarly, claims were more
likely to be supported by referenced studies with identi-
fied funding than studies not indicating the source of
funding (RR 1.50, 95% CI 0.98–2.28).
There were 51 randomised controlled trials among the ref-
erenced studies. In 21% of these trials random allocation
was concealed, 92% were double blind trials, only 6%
reported blinded outcome assessment, 51% reported
complete description of all losses to follow-up and with-
drawals, 23% reported a lost to follow-up of less than
10%, and 75% of trials were analyzed according to the
intention-to-treat principle. There was a trend that claims
referring to studies with double blind design were more
likely to be supported than trials with an open design (RR
1.15, 95%CI 0.94–1.41).
Discussion
In this representative survey on the accuracy of pharma-
ceutical claims in medical journals in Switzerland, only
47% of all claims for analgesic, gastrointestinal and psy-
chopharmacologic drugs were supported by the refer-
enced study. More than half of all claims were not
supported or based on potentially biased information. In
our opinion, these claims are in violation of the Federal
Act on Therapeutic Products regulating the marketing of
medical drugs in Switzerland.
We assessed all pharmaceutical claims referring to analge-
sic, gastrointestinal and psychopharmacologic drugs for
the year 2005 in all issues of six major medical journals in
Switzerland according to predefined criteria. The agree-
ment between the two independent reviewers with respect
to the classification of claims into the three categories of
being supported, not supported or based on potentially
biased referenced studies was substantial, thereby increas-
ing the credibility of our assessment [25].
Our study has a few limitations. Only a small fraction of
all advertisements contained claims referring to scientific
studies. Thus, our analysis is based on relatively few pairs
of claims and referenced studies. Our systematic search
identified 323 advertisements referring to analgesic, gas-
trointestinal and psychopharmacological drugs citing at
least one reference. Claims with vague or general state-
Table 3: Examples of not supported claims
Type Drug Claim Reference Reasons for non-support
False statement Tilur®(Acemetacin) As effective as the best, as 
safe as the
Leeb et al. Orthopädie 33: 
1032–1041, 2004
Only comparator to 
acemetacin was diclofenac 
which is neither the most 
effective nor the safest non-
steroidal antirheumatic drug
Exaggeration of 
efficacy
Relpax® (Eletriptan) Eliminates pain Sandrini G et al. Neurology 
59:1210–1217, 2002
At 24 hours only 24%(40 mg) 
and 29%(80 mg) of patients 
treated with eletriptan were 
pain-free
Unjustified 
generalization
Xefo® (Lornoxicam) Safe for heart and 
circulation
Tsurko V et al. Ter Arkh 
74:63–6, 2002
Only blood pressure and heart 
rate measured. No hard 
endpoints evaluated
Absence of relation Duphalac® (Laktulose) Fast and permanent effect 
on constipation
Ballongue et al. Scand J Gast 
32 Suppl. 222: 41–44, 1997
Constipation not an outcome 
of the study.
Unjustified transfer to 
humans
Duspatalin® (Mebeverin) Effective in all cases of 
irritable bowel syndrome
Boisson J et al. Chir. 
Digest.16: 289–292, 1987
Animal study (pigs)BMC Medical Informatics and Decision Making 2008, 8:61 http://www.biomedcentral.com/1472-6947/8/61
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ments that could not be matched to a referenced study
were excluded from our analysis. After excluding multiple
publications of the same advertisement, we ended up with
78 pairs of claims and referenced studies, because adver-
tisements of the same product were repeatedly placed in
several issues of medical journals. We did not calculate
kappa statistics for all classifications, but limited them to
the classification of the claims as being supported, not
supported or being based on biased evidence. For several
reasons, we limited our assessment of the accuracy of
pharmaceutical claims to drugs that are very frequently
used in primary care for treatment of functional disorders
that are of immanent and immediate importance to
patients. The accuracy of pharmaceutical claims referring
to lipid-lowering and antihypertensive drugs has already
been assessed recently [6]. Furthermore, we hypothesized
that referenced studies relating to analgesic, gastrointesti-
nal and psychopharmacologic drugs may be more prone
to biased interpretation than studies relating to lipid-low-
ering and antihypertensive drugs. Outcomes such as
reduction in pain or symptom scores are harder to quan-
tify and may not be as reliable as opposed to outcomes in
cardiovascular studies such as mortality or myocardial inf-
arction. However, in a study by Villanueva et al. assessing
the accuracy of all advertisement claims for antihyperten-
sive and lipid-lowering drugs in six Spanish medical jour-
nals [6], 44% of promotional statements were not
supported by the cited reference study, only slightly less
than in our study. We used a very similar methodology to
rate advertisement claims like in this study from Spain,
but expanded the assessment on quality aspects of refer-
enced trials. In the study by Villanueva [6], the most com-
mon reason for not supported claims were
recommendations to use the drug in a patient group other
than the one assessed in the referenced study. In our sur-
vey, the most common reasons for not supported claims
were false statements and exaggeration of efficacy. These
differences might be explained by the type of drugs evalu-
ated. Antihypertensive and lipid-lowering drugs are often
evaluated in large scale randomised controlled trials of
highly selected patients powered for clinical endpoints
such as myocardial infarction and overall mortality.
Therefore in the context of aggressive marketing and
expansion of drug use misquotes are more likely to be
related to extrapolation of effects to patient populations
not included into the original trials. In contrast, studies on
analgesic gastrointestinal or psychopharmacologic drugs
are more often evaluated in smaller trials with endpoints
such as pain and symptom relief or quality of life. These
endpoints are often difficult to interpret for clinicians in
the context of the clinical relevance and thus make them
more prone to reports of exaggerated efficacy or false state-
ments.
In a Finnish study assessing the quality of marketing
claims medical journals published in Finland in 2002
[12], only 2% of marketing claims were rated as being
supported by strong scientific evidence. The extremely low
proportion of supported claims in that study, however, is
explained by the fact that authors rated a high number of
marketing claims with vague or emotional statements
(68% of all assessed claims) as not supported by the refer-
Table 4: Examples of claims based on potentially biased evidence
Type Drug Claim Reference Reasons for potential bias
Abstract Pantozol® (Pantoprazol) Similar healing of reflux 
disease as omeprazol 20 mg
Bardnan KD et al. 
Gastroenterology 
116(Suppl.4II): A 118, 1999
Abstract, open study, no 
blinded outcome assessment
Selection Bias Neurodol® (Lidocaine) Neurodol tissugel reduces 
pain and allodynia in 
postherpetic neuralgia
Meier T et al., Pain 106: 
151–158, 2003
Selection bias (only patients 
who had already successfully 
been treated with lidocaine 
for more than 1 month were 
included in study), very few 
patients
Publication bias Lamictal® (Lamotrigine) Well tolerated Bowden CL et al. Drug 
Safety 2004; 57: 173–184
Narrative review, possible 
publication and selective 
reporting of evidence bias
At least 3 quality 
criteria missing
Zoloft® (Sertraline) Increases cognitive capacity Newhouse PA et al. J Clin 
Psych 2000;61:559–68
High drop out rate(>30%), no 
descriptions of losses to 
follow-up, selective reporting 
of positive outcomes
Post hoc analysis Jarsin® (St. John's word) Similar efficacy as synthetic 
antidepressants
Brenner R et al. Clinical 
Therapeutics 22: 411–419, 
2000
Post-hoc analysis, only 15 
patients in each group, no 
sample size calculationBMC Medical Informatics and Decision Making 2008, 8:61 http://www.biomedcentral.com/1472-6947/8/61
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enced study. In contrast, we excluded claims with vague or
general statements that could not be verified by a refer-
enced study from our analysis such as purely descriptive
claims referring to the Swiss Drug Compendium, the
standard reference book for drugs licensed in Switzerland
[24].
In a study evaluating claims of rheumatologic drug adver-
tisements in four rheumatologic specialist journals, 74%
claims were rated as being poorly supported and 8% as
being misleading [28]. However, this study included all
claims with references that related to data on file or offi-
cial prescribing information which then were rated as
poor evidence support whereas we excluded all claims
with references to prescribing or on file information.
We found that studies with conflict of interest and studies
stating industry funding were more likely to support the
corresponding claim, although this particular informa-
tion was missing in the majority of studies. Thus, in this
survey active involvement of the drug manufacturer in the
study seems to be associated with more accurate citation
of study findings and more directive and professional
marketing. However, some of these studies may still have
been biased in ways we could not detect by looking at
study reports alone.
Our findings demonstrate that in Switzerland many phar-
maceutical advertisement claims referencing scientific
information currently do not accord with the Federal Law
on Therapeutic Products [17] and indicate a problematic
discrepancy between current legislation and the existing
passive control mechanisms for the adequacy of drug
advertisements. Publishers of medical journals do not
take responsibility for the content of advertisement claims
and usually exert only rudimentary controls to avoid the
publication of offensive, aggressive, or exaggerated adver-
tisement claims. Swissmedic, the Swiss Agency for Thera-
peutic Products, is responsible to take legal action against
violation of the Federal Act on Therapeutic Products. The
agency must react when informed about inaccurate phar-
maceutical advertisement claims, but has no system in
place to actively survey the adequacy of advertisement
claims of pharmaceutical companies for example by ran-
dom sample checking. This is particularly problematic
since drug advertisement is known to influence prescrip-
tion patterns of physicians. Although physicians perceive
themselves as paying little attention to drug commercials,
some evidence suggests that prescription patterns of phy-
sicians may be influenced by drug advertisements [4,29-
34].
Our study has important implications. Physicians should
not trust pharmaceutical advertisement claims even when
they are referring to scientific studies. Physicians need to
be aware that the pharmaceutical industry may use drug
advertisements to influence prescription patterns even
when this results in distortion of scientific facts. The phar-
maceutical industry should be more responsible and
more meticulous in making sure that pharmaceutical
claims referring to scientific studies are quoted accurately.
Given the magnitude of unsupported drug claims
observed in our study, Swissmedic and similar organiza-
tions in other countries should be required to take an
active monitoring role in checking the accuracy of drug
advertisements. Legal health entities, the pharmaceutical
industry and publishers of medical journals may need to
be held responsible to develop and promote minimal
standards for the publication of pharmaceutical drug
advertisements. Control mechanisms that may be reason-
ably applied like for example a random peer review proc-
ess according to a standardized checklist should be
adopted. Recently, a checklist for reporting an abstract of
a randomized trial has been suggested as a mean to pro-
vide the necessary details and clarity in abstracts allowing
readers to assess the validity and applicability of ran-
domised trial results[35]. A similar instrument could add
to create standards to improve the accuracy of informa-
tion provided in drug advertisement claims.
Conclusion
We conclude that less than half of all advertisement
claims for analgesic, gastrointestinal or psychopharmaco-
logic drugs published in Swiss medical journals were sup-
ported by the referenced studies. Physicians need to be
aware that they can not blindly trust drug advertisement
claims even when they seem to refer to scientific studies.
In our opinion, legal actions such as administrative fines
may be required to ensure systematic monitoring of the
accuracy of pharmaceutical marketing claims in order to
improve the accuracy of pharmaceutical advertisement
claims in the future.
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